Safety assessment of mushroom beta-glucan: Subchronic toxicity in rodents and mutagenicity studies
Resource
FOOD AND CHEMICAL TOXICOLOGY, 49(11), 2890-2898
Journal
FOOD AND CHEMICAL TOXICOLOGY
Journal Volume
49
Journal Issue
11
Pages
2890-2898
Date Issued
2011
Date
2011
Author(s)
Chen, S.N.
Nan, F.H.
Chen, S.
Wu, J.F.
Lu, C.L.
Soni, Madhu G.
Abstract
Mushroom β-glucan, a polymer of β-(1,3/1,6)-glucan, has been claimed for its health benefits. The objective of this study was to assess the safety in-use of mushroom β-glucan as dietary supplement and food ingredient. Hence, a subchronic toxicity and mutagenicity studies were conducted. In the subchronic toxicity study, Sprague Dawley rats (12/sex/group) were administered (gavage) mushroom β-glucan at dose levels of 0, 500, 1000 and 2000 mg/kg body weight (bw)/day for 90 days. As compared to control group, administration of β-glucan did not result in any toxicologically significant treatment-related changes in clinical observations, ophthalmic examinations, body weights, body weight gains, feed consumption, and organ weights. No adverse effects of the β-glucan on the hematology, serum chemistry parameters, urinalysis or terminal necropsy (gross or histopathology findings) were noted. The results of mutagenicity studies as evaluated by gene mutations in Salmonella typhimurium, in vitro chromosome aberrations and in vivo micronucleus test in mouse did not reveal any genotoxicity of β-glucan. Based on the subchronic study, the no observed-adverse-effect level (NOAEL) for mushroom β-glucan was determined as 2000 mg/kgbw/day, the highest dose tested.
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
35.pdf
Size
23.23 KB
Format
Adobe PDF
Checksum
(MD5):29aedb5477f42a155334cb14ab0d1360